Review article: Hepatitis B and dialysis

Nephrology

Volumn 15, Issue 2, 2010, Pages 137-145

  Edey, Matthew ^a   Barraclough, Katherine ^a   Johnson, David W ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

End stage renal failure; Environmental transmission; Haemodialysis; Hepatitis B; Treatment; Vaccine

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HBV AS 04 VACCINE; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; INTERLEUKIN 2; LAMIVUDINE; PEGINTERFERON; PLACEBO; RECOMBINANT HEPATITIS B VACCINE; TELBIVUDINE; TENOFOVIR; THYMOPENTIN; UNCLASSIFIED DRUG; VIRUS DNA;

ADD ON THERAPY; BONE MARROW SUPPRESSION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; EPIDEMIC; FLU LIKE SYNDROME; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; KIDNEY INJURY; KIDNEY TUBULE DISORDER; LIVER CELL CARCINOMA; LOW DRUG DOSE; MORBIDITY; NEPHROTOXICITY; PATIENT SELECTION; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SEROCONVERSION; SEROLOGY; TREATMENT RESPONSE; VACCINATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CARRIER STATE; DNA, VIRAL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INCIDENCE; INFECTION CONTROL; KIDNEY FAILURE, CHRONIC; PATIENT SELECTION; PREVALENCE; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77749322445     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01268.x     Document Type: Review

References (111)

1. Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14-16, 2002. Geneva, Switzerland. J. Hepatol. 2003 39 (Suppl 1 S1 S235.
2. Moloughney BW. Transmission and postexposure management of bloodborne virus infections in the health care setting: Where are we now? CMAJ 2001 165 445 451.
3. Dienstag JL. Hepatitis B virus infection. N. Engl. J. Med. 2008 359 1486 1500.
4. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004 11 97 107.
5. Kane M. Global programme for control of hepatitis B infection. Vaccine 1995 13 (Suppl 1 S47 S49.
6. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 2001 94 153 156. (Pubitemid 32911406)
7. Rosenheim Advisory Group. Hepatitis and the Treatment of Chronic Renal Failure. London : Department of Health and Social Security, 1972.
8. Centers for Disease Control. Hepatitis: Control Measures for Hepatitis B in Dialysis Centers. HEW publication no. (CDC) 78-8358. Altlanta, GA : US Department of Health, Education and Welfare, 1977.
9. Dinits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am. J. Kidney Dis. 2005 46 997 1011.
10. Stevens CE, Szmuness W, Goodman AI, Weseley SA, Fotino M. Hepatitis B vaccine: Immune responses in haemodialysis patients. Lancet 1980 2 1211 1213.
11. Desmyter J, Colaert J, De Groote G et al. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 1983 2 1323 1328.
12. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin. Dial. 2005 18 52 61.
13. Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2003 63 2222 2229.
14. Johnson DW, Dent H, Yao Q et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: Analysis of registry data. Nephrol. Dial. Transplant. 2009 24 1598 1603.
15. Yakaryilmaz F, Gurbuz OA, Guliter S et al. Prevalence of occult hepatitis B and hepatitis C virus infections in Turkish hemodialysis patients. Ren. Fail. 2006 28 729 735.
16. Ferreira RC, Teles SA, Dias MA et al. Hepatitis B virus infection profile in hemodialysis patients in Central Brazil: Prevalence, risk factors, and genotypes. Mem. Inst. Oswaldo Cruz 2006 101 689 692.
17. Carrilho FJ, Moraes CR, Pinho JR et al. Hepatitis B virus infection in Haemodialysis Centres from Santa Catarina State, Southern Brazil. Predictive risk factors for infection and molecular epidemiology. BMC Public Health 2004 4 13.
18. Ribot S, Rothstein M, Goldblat M, Grasso M. Duration of hepatitis B surface antigenemia (HBs Ag) in hemodialysis patients. Arch. Intern. Med. 1979 139 178 180.
19. Wong PN, Fung TT, Mak SK et al. Hepatitis B virus infection in dialysis patients. J. Gastroenterol. Hepatol. 2005 20 1641 1651.
20. Bond WW, Favero MS, Petersen NJ, Gravelle CR, Ebert JW, Maynard JE. Survival of hepatitis B virus after drying and storage for one week [letter]. Lancet 1981 1 550 551.
21. Karkar A, Abdelrahman M, Ghacha R, Malik TQ. Prevention of viral transmission in HD units: The value of isolation. Saudi J. Kidney Dis. Transpl. 2006 17 183 188.
22. Salo RJ, Salo AA, Fahlberg WJ, Ellzey JT. Hepatitis B surface antigen (HBSAg) in peritoneal fluid of HBSAg carriers undergoing peritoneal dialysis. J. Med. Virol. 1980 6 29 35.
23. Oreopoulos DG. Hepatitis and treatment of chronic renal failure by peritoneal dialysis. Lancet 1972 2 1256.
24. Puttinger H, Vychytil A. Hepatitis B and C in peritoneal dialysis patients. Semin. Nephrol. 2002 22 351 360.
25. Hung KY, Shyu RS, Huang CH, Tsai TJ, Chen WY. Viral hepatitis in continuous ambulatory peritoneal dialysis patients in an endemic area for hepatitis B and C infection: The Taiwan experience. Blood Purif. 1997 15 195 199.
26. Centers for Disease Control. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb. Mortal. Wkly. Rep. 2001 50 1 43.
27. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. Morb. Mortal. Wkly. Rep. 2004 50 1 43.
28. United Kingdom Department of Health. Good Practice Guidelines for Renal Dialysis/Transplantation Units. Prevention and Control of Blood-Borne Virus Infection. London : Department of Health, 2002.
29. Community and Hospital Infection Control Association - Canada. Position Statement. Infection Prevention and Control Measures to Prevent Transmission of Hepatitis B among Hemodialysis Patients. Winnipeg : Canada. Community and Hospital Infection Control Association, 2007.
30. Centre for Healthcare Related Infection Surveillance and Prevention. Recommended Practices for the Prevention and Control of Infections in Dialysis Settings. Brisbane : Queensland Health, 2009.
31. Tele SA, Martins RM, Lopes CL, dos Santos Carneiro MA, Souza KP, Yoshida CF. Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff. Eur. J. Epidemiol. 2001 17 145 149.
32. Centers for Disease Control. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm. Rep. 2001 50 1 52.
33. Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G. Patient to patient transmission of hepatitis B virus: A systematic review of reports on outbreaks between 1992 and 2007. BMC Med. 2009 7 15.
34. Centers for Disease Control. Outbreaks of hepatitis B virus infection among hemodialysis patients - California, Nebraska, and Texas, 1994. Morb. Mortal. Wkly. Rep. 1996 45 285 289.
35. Hoofnagle JH. Serologic markers of hepatitis B virus infection. Annu. Rev. Med. 1981 32 1 11.
36. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N. Engl. J. Med. 2004 350 1118 1129.
37. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009 373 582 592.
38. Hui CK, Leung N, Yuen ST et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007 46 395 401. (Pubitemid 47344774)
39. Liaw YF. Hepatitis flares and hepatitis B e antigen seroconversion: Implication in anti-hepatitis B virus therapy. J. Gastroenterol. Hepatol. 2003 18 246 252.
40. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up. Hepatology 2007 45 1187 1192.
41. Fattovich G, Olivari N, Pasino M, D'Onofrio M, Martone E, Donato F. Long-term outcome of chronic hepatitis B in Caucasian patients: Mortality after 25 years. Gut 2008 57 84 90.
42. Di Stefano M, Volpe A, Stallone G et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J. Nephrol. 2009 22 381 386.
43. Janzen L, Minuk GY, Fast M, Bernstein KN. Vaccine-induced hepatitis B surface antigen positivity in adult hemodialysis patients: Incidental and surveillance data. J. Am. Soc. Nephrol. 1996 7 1228 1234.
44. Krugman S, Giles JP, Hammond J. Viral hepatitis, type B (MS-2 strain) prevention with specific hepatitis B immune serum globulin. JAMA 1971 218 1665 1670.
45. Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR. Vaccine against human hepatitis B. JAMA 1976 235 2832 2834.
46. Adkins JC, Wagstaff AJ. Recombinant hepatitis B vaccine: A review of its immunogenicity and protective efficacy against hepatitis B. BioDrugs 1998 10 137 158.
47. Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: Randomised double blind dose-response study. BMJ 1997 314 329 333.
48. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol. Rev. 2006 28 112 125.
49. Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine 1990 8 (Suppl S74 S78.
50. McMahon BJ, Helminiak C, Wainwright RB, Bulkow L, Trimble BA, Wainwright K. Frequency of adverse reactions to hepatitis B vaccine in 43 618 persons. Am. J. Med. 1992 92 254 256.
51. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: Demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N. Engl. J. Med. 1980 303 833 841.
52. Crosnier J, Jungers P, Courouce AM et al. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1981 1 797 800. (Pubitemid 11147433)
53. Köhler H, Arnold W, Renschin G, Dormeyer HH. Meyer zum Buschenfelde KH. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int. 1984 25 124 128.
54. Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N. Engl. J. Med. 1984 311 496 501.
55. Grob PJ, Binswanger U, Zaruba K et al. Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res. 1983 3 43 52.
56. Fujiyama S, Yoshida K, Sato T, Shimada H, Deguchi T. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients. Hepatogastroenterology 1990 37 (Suppl 2 140 144.
57. Bruguera M, Rodicio JL, Alcazar JM, Oliver A, Del Rio G, Esteban-Mur R. Effects of different dose levels and vaccination schedules on immune response to a recombinant DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990 8 (Suppl S47 S49.
58. Peces R, de la Torre M, Alcazar R, Urra JM. Prospective analysis of the factors influencing the antibody response to hepatitis B vaccine in hemodialysis patients. Am. J. Kidney Dis. 1997 29 239 245. (Pubitemid 27130735)
59. Guan R, Tay HH, Choong HL, Yap I, Woo KT. Hepatitis B vaccination in chronic renal failure patients undergoing haemodialysis: The immunogenicity of an increased dose of a recombinant DNA hepatitis B vaccine. Ann. Acad. Med. Singapore 1990 19 793 797.
60. Buti M, Viladomiu L, Jardi R et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am. J. Nephrol. 1992 12 144 147.
61. Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J. Assoc. Physicians India 1999 47 183 185.
62. DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: Earlier is better. Am. J. Kidney Dis. 2003 42 1184 1192.
63. Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as an adjuvant in hepatitis B vaccination of chronic hemodialysis patients who have failed primary vaccination. Clin. Nephrol. 2000 54 138 142.
64. Jungers P, Devillier P, Salomon H, Cerisier JE, Courouce AM. Randomised placebo-controlled trial of recombinant interleukin-2 in chronic uraemic patients who are non-responders to hepatitis B vaccine. Lancet 1994 344 856 857.
65. Miquilena-Colina ME, Lozano-Rodriguez T, Garcia-Pozo L et al. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: Results of a randomised clinical trial. Vaccine 2009 27 5654 5660.
66. Quiroga JA, Castillo I, Porres JC et al. Recombinant gamma-interferon as adjuvant to hepatitis B vaccine in hemodialysis patients. Hepatology 1990 12 661 663.
67. Fabrizi F, Ganeshan SV, Dixit V, Martin P. Meta-analysis: The adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease. Aliment. Pharmacol. Ther. 2006 24 789 796. (Pubitemid 44244902)
68. Tong NK, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 2005 68 2298 2303. (Pubitemid 43117807)
69. Kong NC, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 2008 73 856 862.
70. Chen W, Gluud C. Vaccines for preventing hepatitis B in health-care workers. Cochrane Database Syst. Rev. 2005 CD000100.
71. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: Intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment. Pharmacol. Ther. 2006 24 497 506.
72. Chau KF, Cheng YL, Tsang DN et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: A comparison with the intramuscular vaccination. Am. J. Kidney Dis. 2004 43 910 917.
73. Bock M, Barros E, Veronese FJ. Hepatitis B vaccination in haemodialysis patients: A randomized clinical trial. Nephrology (Carlton) 2009 14 267 272.
74. Barraclough KA, Wiggins KJ, Hawley CM et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: A prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am. J. Kidney Dis. 2009 54 95 103.
75. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol. Dial. Transplant. 1997 12 1204 1211.
76. Weinstein T, Chagnac A, Boaz M et al. Improved immunogenicity of a novel third-generation recombinant hepatitis B vaccine in patients with end-stage renal disease. Nephron Clin. Pract. 2004 97 c67 c72.
77. Rostaing L, Chatelut E, Payen JL et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: Clinical implications. J. Am. Soc. Nephrol. 1998 9 2344 2348.
78. Girndt M. Viral hepatitis in elderly haemodialysis patients: Current prevention and management strategies. Drugs Aging 2008 25 823 840.
79. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Int. 2008 2 163 178.
80. Johnson MA, Verpooten GA, Daniel MJ et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of haemodialysis. Br. J. Clin. Pharmacol. 1998 46 21 7.
81. Asari A, Iles-Smith H, Chen YC et al. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure. Br. J. Clin. Pharmacol. 2007 64 738 744.
82. Ben Ari Z, Broida E, Kittai Y, Chagnac A, Tur-Kaspa R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am. J. Gastroenterol. 2000 95 3579 3583.
83. Lapinski TW, Flisiak R, Jaroszewicz J, Michalewicz M, Kowalczuk O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol. 2005 11 400 402.
84. Fontaine H, Thiers V, Chretien Y et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 2000 69 2090 2094.
85. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 1267 1273.
86. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA 1999 282 2305 2312.
87. Izzedine H, Hulot JS, Launay-Vacher V et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004 66 1153 1158.
88. Ha NB, Ha NB, Garcia RT et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009 50 727 734.
89. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005 352 2673 2681.
90. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 1743 1751.
91. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007 133 1445 1451.
92. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005 80 1086 1092.
93. Tillmann HL, Bock CT, Bleck JS et al. Successful treatment of fibrosing cholestatic hepatitis using adefovir dipivoxil in a patient with cirrhosis and renal insufficiency. Liver Transpl. 2003 9 191 196.
94. Gish RG, Lok AS, Chang TT et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007 133 1437 1444.
95. Leung N, Peng CY, Hann HW et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir. Hepatology 2009 49 72 9.
96. Lok AS, McMahon BJ. Chronic hepatitis B: Update 2009. Hepatology 2009 50 661 662.
97. Jones R, Stebbing J, Nelson M et al. Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: A cohort and case-control study. J. Acquir. Immune Defic. Syndr. 2004 37 1489 1495.
98. Patel SM, Zembower TR, Palella F, Kanwar YS, Ahya SN. Early onset of tenofovir-induced renal failure: Case report and review of the literature. ScientificWorldJournal 2007 7 1140 1148.
99. Kapitsinou PP, Ansari N. Acute renal failure in an AIDS patient on tenofovir: A case report. J. Med. Case Rep. 2008 2 94.
100. Verhelst D, Monge M, Meynard JL et al. Fanconi syndrome and renal failure induced by tenofovir: A first case report. Am. J. Kidney Dis. 2002 40 1331 1333.
101. Izzedine H, Launay-Vacher V, Jullien V, Aymard G, Duvivier C, Deray G. Pharmacokinetics of tenofovir in haemodialysis. Nephrol. Dial. Transplant. 2003 18 1931 1933.
102. Kearney BP, Yale K, Shah J, Zhong L, Flaherty JF. Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment. Clin. Pharmacokinet. 2006 45 1115 1124.
103. Liaw YF, Leung N, Kao JH et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update. Hepatol. Int. 2008 2 263 283.
104. Guh JY, Lai YH, Yang CY et al. Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients. Nephron 1995 69 459 465.
105. Harnett JD, Parfrey PS, Kennedy M, Zeldis JB, Steinman TI, Guttmann RD. The long-term outcome of hepatitis B infection in hemodialysis patients. Am. J. Kidney Dis. 1988 11 210 213.
106. Fabrizi F, Mangano S, Alongi G et al. Influence of hepatitis B virus virema upon serum aminotransferase activity in dialysis population. Int. J. Artif. Organs 2003 26 1048 1055.
107. Fabrizi F, Lunghi G, Alongi G et al. Biological dynamics of hepatitis B virus load in dialysis population. Am. J. Kidney Dis. 2003 41 1278 1285.
108. Tseng GY, Lin HJ, Fang CT et al. Hemodialysis reduces the viral load in uremic patients with chronic hepatitis B infection. Ren. Fail. 2008 30 1000 1005.
109. Barcena MR, Garcia GS. DNA-guided hepatitis B treatment, viral load is essential, but not sufficient. World J. Gastroenterol. 2009 15 : 423 430.
110. Fabrizi F, Messa P, Martin P. Hepatitis B virus infection and the dialysis patient. Semin. Dial. 2008 21 440 446.
111. Gane E, Pilmore H. Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002 74 427 437.